Pairs Unnatural Products’ (UNP) peptide expertise with argenx's antibody engineering, expanding the ways to target novel biologyExtends argenx’s immunology innovation to more patients, with the potential for oral
Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion Acquisition builds on the
ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM populationFirst Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ:ARGX). Such investors are advised to contact
November 3, 2026 Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ:ARGX). Such investors are advised to contact
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ:ARGX). Such investors are advised to contact
Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on track for
Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DMPatient
October 15, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22,
Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("Argenx" or "the Company")
ARGX share price fell sharply after a futility finding resulted in the discontinuation of a pending Phase 3 trial. SueWallSt notifies investors of a pending investigation.NEW YORK, Oct. 8, 2026 /PRNewswire/ -- argenx SE
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac diseaseargenx
October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of
New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patientsReal-world evidence from more than 1,100
